Thursday, July 30, 2026

 

 

Teva CEO on Drug Pipeline, Direct Listing on NYSE

(7/30, Bloomberg) ...Teva Pharmaceuticals CEO Richard Francis speaks to Bloomberg's Romaine Bostick about the company's positive Q2 earnings, the impending impact of changing Medicare rules on patients, and the new listing on the NYSE... Sub. Req'd

 

Watch CNBC's Full Interview with Teva Pharmaceuticals CEO Richard Francis

(7/29, CNBC) ...Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business and more... Full

 

Teva's Innovation Engine Offsets Generics Slump, Leaving One Analyst 'Shocked' by Ajovy's Surge

(7/29, Fraiser Kansteiner, Fierce Pharma) ...Reflecting on Ajovy's recent success, Teva CEO Richard Francis told Fierce in an interview Wednesday that the migraine prevention med had "been sort of given up on" due to a competitive market and "sluggish" sales when he joined the company years ago...With Francis at the helm, "we decided that we needed to really, really go for it," the CEO said. Since prioritizing the branded migraine drug, the company has "seen this product grow across all of our regions," he said. Francis added that Ajovy now "consistently grows faster than the market," crediting Teva's focused execution for the fact that it is "outcompeting" its rivals and taking market share "wherever we sell it."... Full

 

Teva CEO Says There's Time to Prepare for Trump's Tariffs on Generics

(7/29, Ayisha Sharma, Endpoints News) ...Teva is betting it has enough room to adequately prepare for steep tariffs the Trump administration plans to slap on generic drugs made outside the US. "We are at the table and we'll be able to evaluate exactly what the government is trying to do and then understand how we respond to that," CEO Richard Francis told Endpoints News in an interview... Sub. Req'd

 

Teva Pharm Seeking Details on Trump Drug Tariffs Plan, CEO says

(7/29, Reuters) ..."We've got to seek to understand what is the U.S. administration is trying to do," Francis told Reuters after issuing second-quarter financial results, noting Teva is a major player in the U.S. healthcare ecosystem... Full

 

Teva Pharm Profit Misses Estimates, Seeks US Tariff Details

(7/29, Reuters) ...CEO Richard Francis told Reuters he expects the Emalex acquisition to be accretive, but unlikely until at least 2028 — after the likely launch of a Tourette syndrome drug next year... Full

 

Teva Targets Forty Biosimilars As Generics Growth Stalls

(7/29, Dean Rudge, Generics Bulletin) ...Speaking on Teva's second-quarter earnings call earlier today, CEO Richard Francis noted that the company has 15 biosimilars on the market and 14 more moving toward launch, with additional products expected to enter the portfolio through business-development agreements. "We have 14 more to launch, and we can consistently add more to that portfolio," Francis said. "We'll end up with a portfolio, you know, mid-30s, close to 40. That's our ambition."... Global Sub. Full

 

Teva's Q2 Print Paints Rosy Outlook for Innovative Portfolio

(7/29, Elizabeth S. Eaton, FirstWord PHARMA) ...Internally, Teva is also advancing duvakitug, an anti-TL1A mAb with positive data in ulcerative colitis and Crohn's disease, as well as TEV-'408, an IL-15–targeting mAb for vitiligo... Full

 

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations

(7/29, Catherine Dunn, Kit Norton, Barron's) ...On Wednesday's earnings call, CEO Richard Francis said Teva has the potential to launch one new product a year for the next five years, "transforming Teva into a leading biopharma company." Additional indications for medicines could provide further upside through 2035, Francis said... Full

 

Teva's $40 Billion Comeback Brings Wall Street's Biggest Prize into View

(7/30, Sophie Shulman, CTech) ...Wall Street has embraced the moves led by CEO Richard Francis, who in just a few years has transformed Teva from a company identified primarily as a generic-drug giant into a pharmaceutical company focused on higher-margin innovative medicines. The transformation has not only restored investor confidence in the stock but has also changed the way the market values the company... Full

 

 

Trump Ends Prescription Drug Subsidy in Latest Medicare Shakeup

(7/30, Ganny Belloni, Bloomberg Law) ...On Wednesday, the Congressional Budget Office released a report finding that its savings projections for Democrats' 2022 law were wrong. Originally, the office expected drug price negotiations and drug manufacturer inflation rebates would offset the costs of the Medicare Part D redesign, reducing the deficit by $129 billion from 2022-2031. The cost for the redesign, however, was much higher than expected, with the agency now expecting the law to increase the federal deficit over the same period. CMS Administrator Mehmet Oz said pulling the plug on the program would "stabilize" the market so that bailouts were no longer needed... Full

 

Sanctions Bill Gives Trump Sweeping New Tariff Powers

(7/29, Alan Rappeport, The New York Times) ...The policy could lead to additional levies on billions of dollars' worth of products imported from China, India and European Union countries. The bill represents the latest move by Congress to cede more of its authority over trade policy to Mr. Trump. It also comes amid bipartisan anger over the president's provocative use of tariffs, which has led to retaliation from other countries and uncertainty for businesses... Sub. Req'd

 

U.S. Dependence on China Is a National Security Risk

(7/30, Prashant Yadav, Thomas J. Bollyky, Rush Doshi, Paul Friedrichs, Victor Suarez, STAT+) ...The answer to reducing pharmaceutical dependence on China is disciplined, coordinated industrial policy that maximizes U.S. advantages, not blunt tariff-based protectionism, loosely defined multilateral partnerships, or lambasting U.S. companies and regulators alone... Sub. Req'd

 

Assessing The Value Of Post-Approval Research For U.S. Policy Makers

(7/29, Dan Crippen, Kirsten Axelsen, Health Affairs) ...In this article, we describe how post-approval drug development contributes to treatment options for patients. We consider certain implications of price setting for post-approval investment in drug development. We then propose a research agenda that would draw on evidence from public and private sources to evaluate the impact of price-setting policies on post-approval research and development (R&D)... Full

 

FDA Drops Capacity Planning Adjustment For User Fee Updates

(7/29, Jessica Karins, Inside Health Policy) ...The total PDUFA revenue for fiscal 2027, before inflation adjustments, is estimated as $1,515,410,160, a 5.85% increase over fiscal 2026. The baseline fees, which will take effect Oct. 1, are $4,600,753 for applications requiring covered clinical data and $2,300,376 for applications not requiring covered clinical dat... Sub. Req'd

 

US FDA DOGE Cuts, Layoffs Likely Fueled FY 2027 PDUFA Fee Drop

(7/29, Derrick Gingery, Pink Sheet) ...The 1.7% reduction of the prescription drug user fee for applications requiring clinical data in fiscal year 2027 that was announced July 29 occurred in part because the FDA's PDUFA carryover balance is expected to be too large...FDA officials wrote in a Federal Register notice announcing the new fees that the PDUFA reserve was expected to include funding for more than 18 weeks of operations by the end of FY 2026. By law, it cannot have more than 14 weeks of funding... Global Sub. Full

 

 

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

(7/30, Pfizer) ...Across the studies, both the 50 and 100 milligram doses of LITFULO delivered significant, clinically meaningful improvements over placebo on co-primary endpoints for the facial and total body Vitiligo Area Scoring Index, or VASI. Based on these results, Pfizer intends to submit global regulatory filings for LITFULO as a potential new oral systemic therapy for NSV for adults... Full

 

 

Sun Pharma Wins Marketing Approval for Semaglutide in Brazil

(7/30, Economic Times) ...Sun Pharma plans to launch the product in the next few days through a local partnership with Hypera Pharma... Full

 

Feeding Frenzy Looms For Bridion Generics After First US Launches

(7/29, Dave Wallace, Generics Bulletin) ...Companies confirming launch into the market for the $1.6bn brand include Dr Reddy's, Gland Pharma, Glenmark and Hikma...Other firms with approved sugammadex ANDAs include Aspiro, B Braun, Fresenius Kabi, Lupin, Mankind, MSN and Mylan, as well as Qilu Pharm, Sandoz, Sun Pharma, Tamarang, Teva, Zenara and Zydus... Global Sub. Full

 

Samsung Bioepis' Relaunched Lucentis Biosimilar Priced Above Originator

(7/30, Urte Fultinaviciute, Generics Bulletin) ...According to the firm's quarterly biosimilars report, Byooviz's ASP stands at $1,190 in Q3 2026, nearly four times higher than the approximate price of $300 in the previous quarter. Samsung Bioepis confirmed to Generics Bulletin that the price was adjusted upon the biosimilar's relaunch by a new commercial partner... Global Sub. Full

 

Alvotech Marks Key Milestone As FDA Closes Inspection Of Reykjavik Facility; Stock Up

(7/29, TajSabreen Ahamed, RTTNews) ...Alvotech CEO Lisa Graver said the closure reflects the company's ongoing commitment to strengthening its quality systems and manufacturing operations. She added "We continue to work with the FDA to advance our recent Biologics License Applications towards approval."... Full

 

Generics Bulletin's Top 50 Ranking For 2026

(7/29, Dave Wallace, Generics Bulletin) ...This article compiles all the data from Generics Bulletin's 2026 ranking of the Top 50 companies across the generics and biosimilars industry, including additional details of how the firms' financial figures compare... Global Sub. Full

 

 

Sanofi's New CEO 'Looking Deeply' at Late-Stage Pipeline as Clinical Clearout Continues

(7/30, James Waldron, Fierce Biotech) ...[T]he CEO is looking to "simplify the way we make decisions."..."Our principle is quite straightforward," she explained on the July 30 call. "We will continue to invest where science is strongest, where unmet medical need is greatest, and where we can create sustainable long-term value."... Full

 

Bristol Myers Raises 2026 Forecast as Eliquis, Newer Medicines Power Results

(7/30, Michael Erman, Reuters) ..."Our growth portfolio grew 15% in Q2," Chief Commercialization Officer Adam Lenkowsky said in an interview. "We now have nine products that were growing double digits, and these are all medicines that are early in their life cycle."... Full

 

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

(7/29, Grace Yoon, The Wall Street Journal) ...John Reed, Johnson & Johnson's executive vice president of innovative medicine research and development, said by working with Sail the company would aim to accelerate the development of innovative therapies. Under the agreement, Johnson & Johnson would make total initial payments of $785 million, including a $465 million equity investment, and additional contingent payments of $140 million if certain development milestones are achieved... Sub. Req'd

 

'We Have What We Need to Grow:' Biogen CEO Happy to Ease off the M&A for a While

(7/29, Will Maddox, Fierce Biotech) ..."There's been a significant growth in the breadth of our portfolio," the CEO said on the call. "That's exciting, but it also means that now we are shifting to not just growing the substrate of growth, but now executing on that growth story."..."We have what we need to grow near term," he added. "I think we'll be less intentional about M&A and perhaps more opportunistic, but we'll certainly be intentional about early-stage development." If opportunities do arise, they will likely involve assets between the development and IND stage, Viehbacher added... Full

 

GSK, Relation Deepen AI Drug Discovery Alliance with New $110m Deal

(7/30, Pavan Kamat, FirstWord PHARMA) ...Under the agreement, Relation will produce large-scale perturbation datasets from advanced human cellular disease models to map biological pathways and enable the development, validation and training of foundation models for identifying novel therapeutic opportunities. The London-based AI biotech stands to receive upfront and success-based milestone payments... Full

 

Merck KGaA to Adopt Evinova AI-Native Platform to Accelerate Clinical R&D

(7/29, Patrick Lavery, Contract Pharma) ...Evinova's platform covers all modules of study design, document authoring, and downstream automation. According to the company, these capabilities can collectively significantly reduce time, costs, and operational bottlenecks in clinical development... Full

 

Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 7c ; Offers Guidance

(7/30, StreetInsider.com) ...Amneal Pharmaceuticals reported Q2 EPS of $0.30, $0.07 better than the analyst estimate of $0.23. Revenue for the quarter came in at $796.2 million versus the consensus estimate of $758.24 million... Sub. Req'd

 

 

European Commission Backs Member States As MFN Pressure Builds

(7/29, Francesca Bruce, Pink Sheet) ...Collaborative procurement through the forthcoming Critical Medicines Act and EU-level voluntary cooperation mechanisms could help the bloc deal with higher medicine prices driven by US Most Favored Nation (MFN) policy, the European Commission has told the Pink Sheet... Global Sub. Full

 

India's Ethics Committee Crackdown, Trial Acceleration Effort Are Not At Odds: Parexel Exec

(7/29, Vibha Ravi, Pink Sheet) ...In an interview with Pink Sheet, Parexel's Sanjay Vyas, spoke on a range of topics including ACRO and the Indian Society for Clinical Research's (ISCR) attempts to expand India's mind share for global trials and how a recent regulatory advisory could significantly accelerate commencement of clinical trials in the country... Global Sub. Full

 

Note: Article links may expire over time or require a free registration. All news articles are the property of their respective publishers and copyright holders. [contextual emphasis added].

 

Teva global subscription access: registration is required to access FirstWord Pharma+ News and The Generics Bulletin. Please note you must be on the Teva Network (in a Teva location or connected via VPN) to access Teva's InfoNOW news resources. If you have any questions or issues, please email InfoNOW@tevapharm.com.

•      FirstWord Pharma+ News registration: first-time users, register here with your Teva email address. You will automatically receive a daily FirstWord Pharma+ newsletter; click on any news item to access your account.

•      Generics Bulletin, Pink Sheet, Scrip (Citeline) registration: go to the Generics Bulletin site and choose "Sign In" in the upper right-hand corner. First-time users, choose "Sign Up Here" and enter your Teva email address.